ArticleProceedings of the National Academy of Sciences of the United States of America2013
Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.The New England journal of medicine · 2019Trial
- Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.The New England journal of medicine · 2019Trial
- Liver-targeted polymeric prodrugs delivered subcutaneously improve tafenoquine therapeutic window for malaria radical cure.Science advances · 2024Article
- Mechanisms of 8-aminoquinoline induced haemolytic toxicity in a G6PDd humanized mouse model.Journal of cellular and molecular medicine · 2022Article
- Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183.Nature communications · 2022Article
- Primaquine as a Candidate for HHV-8-Associated Primary Effusion Lymphoma and Kaposi's Sarcoma Treatment.Cancers · 2022Article
- Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency.Pharmacology & therapeutics · 2021Review
- Article
- Tafenoquine: A Step toward Malaria Elimination.Biochemistry · 2020Article
- Discovery of Small-Molecule Activators for Glucose-6-Phosphate Dehydrogenase (G6PD) Using Machine Learning Approaches.International journal of molecular sciences · 2020Article
- Heterogeneous Network Model to Identify Potential Associations BetweenInternational journal of molecular sciences · 2020Article
- 8-Aminoquinoline Therapy for Latent Malaria.Clinical microbiology reviews · 2019Review
- Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics.Pharmaceutical research · 2018Review
- UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.Antimicrobial agents and chemotherapy · 2018Article
- [Expression ofZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2018Article
- Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (The American journal of tropical medicine and hygiene · 2017Article
- Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum.International journal for parasitology. Drugs and drug resistance · 2017Article
- A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.Nature communications · 2017Article
- New developments in anti-malarial target candidate and product profiles.Malaria journal · 2017Review
- Translational Rodent Models for Research on Parasitic Protozoa-A Review of Confounders and Possibilities.Frontiers in cellular and infection microbiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals with glucose 6-phosphate dehydrogenase (G6PD) deficiency are at risk for the development of hemolytic anemia when given 8-aminoquinolines (8-AQs), an important class of antimalarial/antiinfective therapeutics. However, there is no suitable animal model that can predict the clinical hemolytic potential of drugs. We developed and validated a human (hu)RBC-SCID mouse model by giving nonobese diabetic/SCID mice daily transfusions of huRBCs from G6PD-deficient donors. Treatment of SCID mice engrafted with G6PD-deficient huRBCs with primaquine, an 8-AQ, resulted in a dose-dependent selective loss of huRBCs. To validate the specificity of this model, we tested known nonhemolytic antimalarial drugs: mefloquine, chloroquine, doxycycline, and pyrimethamine. No significant loss of G6PD-deficient huRBCs was observed. Treatment with drugs known to cause hemolytic toxicity (pamaquine, sitamaquine, tafenoquine, and dapsone) resulted in loss of G6PD-deficient huRBCs comparable to primaquine. This mouse model provides an important tool to test drugs for their potential to cause hemolytic toxicity in G6PD-deficient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.